옥시모르폰

옥시모르폰
옥시모르폰 구조식 이미지
카스 번호:
76-41-5
한글명:
옥시모르폰
동의어(한글):
옥시모르폰
상품명:
OXYMORPHONE
동의어(영문):
NSC 19045;NIH 10323;Numorphan;Oxymorphine;OXYMORPHONE;Oxymorphone (CRM);Dihydroxymorphinone;Naltrexone Impurity 15;OXYMORPHONE (MW 301.35);Dihydrohydroxymorphinone
CBNumber:
CB8317944
분자식:
C17H19NO4
포뮬러 무게:
301.34
MOL 파일:
76-41-5.mol

옥시모르폰 속성

녹는점
248-249°C (dec)
끓는 점
518.6±50.0 °C(Predicted)
밀도
1.50±0.1 g/cm3(Predicted)
인화점
9℃
저장 조건
Controlled Substance, -20°C Freezer
용해도
DMSO에 용해됨
물리적 상태
가루
산도 계수 (pKa)
pKa 8.50 (Uncertain);9.33 (Uncertain)
EPA
Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, (5.alpha.)- (76-41-5)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 F,T,T+
위험 카페고리 넘버 11-23/24/25-39/23/24/25-26/27/28
안전지침서 16-36/37-45-36/37/39-22
유엔번호(UN No.) UN1230 - class 3 - PG 2 - Methanol, solution
WGK 독일 1
HS 번호 2939110000
유해 물질 데이터 76-41-5(Hazardous Substances Data)
그림문자(GHS): GHS hazard pictograms
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H302 삼키면 유해함 급성 독성 물질 - 경구 구분 4 경고 GHS hazard pictograms P264, P270, P301+P312, P330, P501
H336 졸음 또는 현기증을 일으킬 수 있음 특정표적장기 독성 물질(1회 노출);마취작용 구분 3 경고 P261, P271, P304+P340, P312,P403+P233, P405, P501
예방조치문구:
NFPA 704
3
0 0

옥시모르폰 C화학적 특성, 용도, 생산

화학적 성질

Crystalline Solid

용도

Controlled substance (opiate). Analgesic (narcotic)

Biological Functions

Oxymorphone is 10 times as potent as morphine, with actions similar to those of hydromorphone. Oxymorphone, however, has little antitussive activity, and as such is a useful analgesic in patients with pulmonary disease who need to retain the ability to cough.

일반 설명

Oxymorphone is the 14 beta-hydroxyl version of hydromorphone,analogous to the hydrocodone, oxycodone pair discussedabove. Although the addition of the 14 beta-hydroxylgroup to hydrocodone (30 mg) yielded oxycodone (20 mg),a more potent drug, the opposite is true for the conversion ofhydromorphone (7.5 mg) to oxymorphone (10 mg). The reasonfor this is that the oral bioavailability of oxymorphone(10%) is lower than that of hydromorphone (35%) becauseof decreased absorption and increased first-pass metabolism.Presumably, the addition of the OH group does increaseits binding affinity at the receptor as the injectableform of oxymorphone (1 mg) is more potent than injectablehydromorphone (1.5 mg).
Oxymorphone is available as a suppository (5 mg), an injection(1 mg/mL), an immediate-release tablet (5 mg, 10mg), and in 2003 the FDA approved a sustained release formulation(Opana ER 5 mg, 10 mg, 20 mg, and 40 mg). The12-hour coverage of the extended release tablet provides anotheroption for those patients suffering from chronic pain.The side effect profile of the extended release formulationsof morphine, oxycodone, and oxymorphone are similar, andthere appears to be no clear advantage of one over the other.

옥시모르폰 준비 용품 및 원자재

원자재

준비 용품


옥시모르폰 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved